Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Capital Expenditures (2020 - 2021)

Design Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $1.4 million for Q4 2021.

  • For Q4 2021, Capital Expenditures rose 10085.71% year-over-year to $1.4 million; the TTM value through Dec 2021 reached $1.5 million, changed N/A, while the annual FY2025 figure was $193000.0, 43.24% down from the prior year.
  • Capital Expenditures for Q4 2021 was $1.4 million at Design Therapeutics, up from -$104000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.4 million in Q4 2021 and bottomed at -$104000.0 in Q3 2021.